Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Apr 7;139(14):2252–2256. doi: 10.1182/blood.2021013926

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by The American Society of Hematology

PMC Copyright notice

Figure 1. — scRNA-seq analysis of immune cells from nonprogressive MBL patients and CLL patients. (A) PBMCs from 2 serial samples were collected for 3 patients with MBL and 7 with CLL. (B) Non-CD19⁺CD5⁺ cells were isolated by fluorescence-activated cell sorting. UMAP visualization of all immune cells colored by immune cell type (top) and CLL or MBL assignment (bottom). (C) Proportion of immune cell types per time point in patients with MBL or CLL. (D) Proportion of T-cell types per time point in patients with MBL or CLL. Cell percentages were calculated after the number of cell from all samples. CTL, cytotoxic T lymphocyte; DC, dendritic cell; gdT, γ-δ T (cells); ILC, innate lymphoid cell; MAIT, mucosa-associated invariant T (cells); Mono, monocyte; NK, natural killer (cell); pDC, plasmacytoid dendritic cell; T, T cell; TCM, central memory T (cell); TEM, effector memory T (cell); Treg, regulatory T (cells).